Clinical trial
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic…
NCT00019383 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019383 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma |
| Official title | Immunization of Patients With Metastatic Melanoma Using Immunodominant Peptides From the Tyrosinase Protein or Tyrosinase Related Protein-1 (TRP1) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide, tyrosinase-related protein-1 |
| Start date | Jan 1, 1998 |
| Completion | Jun 1, 2003 |
| First posted | Aug 7, 2003 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: